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Better treatment of XDR 
tuberculosis needed in 
South Africa
Elize Pietersen and colleagues 
(April 5, p 1230)1 show the very 
poor outcomes for treatment of 
extensively drug-resistant (XDR) 
tuberculosis in South Africa. The 
study suggests that large numbers 
of patients, for whom treatment was 
ineffective, pose a risk of ongoing 
community transmission.
Although we support the provision 
of community-based care minimising 
transmission risk after treatment 
failure, we would also like to put 
these numbers into context. More 
than 1500 XDR tuberculosis cases are 
diagnosed in South Africa annually,2 
likely representing a fraction of 
the actual burden. In view of that 
less than half of people diagnosed 
receive treatment, the combination 
of undiagnosed and untreated 
XDR-tuberculosis poses a much larger 
risk in our communities than the 
small number of patients discharged 
with treatment failure Pietersen and 
colleagues describe.1
Rather than emphasising the 
risk from these few patients, the 
focus should be directed towards 
early diagnosis and rapid initiation 
of effective treatment for all 
drug-resistant tuberculosis cases, 
including individuals unfortunate 
enough to have contracted 
XDR-tuberculosis. South African 
guidelines describe individualised 
X D R- t u b e r c u l o s i s  t r e a t m e n t , 
including the use of linezolid and 
clofazamine.3 Unfortunately, access 
to both these drugs is restricted; 
clofazamine due to supply issues 
and linezolid due to high costs 
charged by Pfizer in the absence 
of a registered generic alternative. 
Early XDR-tuberculosis diagnosis, 
treatment with more drugs 
(including linezolid and new drugs 
via expanded access), and particularly 
timely initiation of antiretroviral HIV 
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We thank Aurélien  Dupré and 
colleagues for their interest in 
our Article.1 So far, most research 
into adhesions has focused on the 
consequences and prevention of 
small bowel obstruction, which is 
shown by the results presented in 
our meta-analysis. However, there 
is growing evidence suggesting 
that difficulties and subsequent 
iatrogenic injuries in reoperations 
are an even larger health problem 
in terms of morbidity and costs.2 
Dupré and colleagues justly remark 
that the burden of adhesiolysis is 
only expected to rise further with the 
increasing number of reoperations in 
oncological surgery.
Although somewhat outside the 
scope of our systematic review, these 
new epidemiological data warrant 
a change in the understanding of 
adhesion-related morbidity and 
strategies for adhesion prevention. 
Previous cost-effectiveness models 
for adhesion barriers that focused on 
prevention of adhesive small bowel 
obstruction demonstrated that 
these agents might be cost eﬀ ective 
for only selected patients.3 A more 
complete cost-effectiveness model 
would also account for the additional 
costs made in reoperations and 
fertility and chronic visceral pain 
treatments. A more comprehensive 
model is expected to show that 
barriers are cost effective in most 
patients who undergo abdominal 
surgery because reduction of 
adhesion formation would already 
provide a beneﬁ t.
For explanation, the difficulty in 
prevention of adhesive small bowel 
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obstruction is that small bowel 
obstruction can be caused by just 
one adhesive band and prevention 
of small bowel obstruction therefore 
requires total adhesion prevention 
in the whole peritoneal cavity, which 
is relatively difficult to achieve. 
The complications of adhesiolysis 
during reoperation are correlated to 
the extent and severity of adhesion 
formation.4 Thus, although the use 
of adhesion reducing agents might 
not completely prevent adhesion 
formation in operations with 
extensive peritoneal damage and 
have only a modest effect on the 
incidence of small bowel obstruction, 
reducing the extent and severity of 
adhesions is likely to have a beneﬁ cial 
effect on the outcomes of future 
operations.
These new data have consequences 
for the design of future trials on 
adhesion prevention. Dupré and 
colleagues were one of the first to 
study the eﬀ ect of adhesion barriers 
on adhesiolysis time in two-stage 
oncological liver surgery.5 Whether 
this reduction of adhesiolysis time is 
indeed correlated to a reduction in 
iatrogenic bowel injury and serious 
adverse events of the reoperation 
needs validation in larger trials.
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treatment, would all be expected to 
improve treatment outcomes over 
what is described.4,5 Prevention of 
treatment failure saves lives and is the 
best infection control.
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Author’s reply
We agree entirely that the focus 
of the South African Department 
of Health and other stakeholders 
attempting to achieve tuberculosis 
control should be directed towards 
early diagnosis and rapid initiation 
of effective treatment for all 
drug-resistant cases, including those 
with extensively drug-resistant 
(XDR) tuberculosis. Our objective was 
not to preferentially emphasise or 
detract from any particular aspect of 
tuberculosis control. Clearly, control 
of drug-resistant tuberculosis requires 
a multifaceted approach addressing 
socioeconomic factors, education, 
preventive strategies, early and rapid 
diagnosis, initiation of effective 
treatment, and social and sex-based 
issues, amongst others. Although 
all these are important, including 
the points raised by Helen Cox and 
colleagues, there is also the issue 
of appropriate care for patients 
discharged into the community who 
are therapeutically destitute (patients 
for whom there are no further 
therapeutic options because of very 
high grade resistance)1 within the 
context of the South African National 
TB Programme. We have previously 
raised our concerns regarding 
community-based transmission.2,3 
In particular, we need a coordinated 
national strategy in South Africa 
that combines home-based care 
with long-term community stay 
facilities, and appropriate palliative 
care facilities. The reality is that such 
facilities are virtually non-existent in 
South Africa and there is an urgent 
need to provide such facilities until 
more effective drug regimens and 
interventions are available.
Although there  are  many 
priorities including protection of 
health-care workers,4 we believe an 
important area of emphasis should 
be strengthening of the national 
tuberculosis  prog ramme and 
trialling and introducing an eﬀ ective 
regimen for multidrug-resistant 
tuberculosis. As Cox and colleagues 
point out, we do not have eﬀ ective 
drugs to deal with the problem and 
thus introduction of newer drug 
regimens for tuberculosis, including 
drug-resistant tuberculosis, remain a 
major priority.
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